Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11240967 | 0.87 | LMNA (0.42) | LMNAALDH1A1NPSR1TSHRCYP2C19 | |
| SCHEMBL558740 | 0.82 | — | — | |
| SCHEMBL14498365 | 0.79 | AKR1C3 (0.38) | AKR1C3ALDH1A1NPSR1TSHRCYP2C19 | |
| SCHEMBL2325561 | 0.78 | CA1 (0.40) | AKR1C3 | |
| SCHEMBL667021 | 0.78 | — | — | |
| SCHEMBL9320850 | 0.76 | LMNA (0.34) | LMNAALDH1A1NPSR1TSHRCYP2C19 | |
| SCHEMBL196906 | 0.72 | LMNA (0.42) | LMNAALDH1A1NPSR1TSHRCYP2C19 | |
| SCHEMBL30241067 | 0.71 | AKR1C3 (0.36) | AKR1C3 | |
| SCHEMBL771276 | 0.70 | KMT2A (0.35) | LMNAALDH1A1TSHRCYP2C19SMN1; SMN2 | |
| SCHEMBL30009461 | 0.68 | JAK1 (0.34) | AKR1C3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2831064-B1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-17 | — | — | EP | claimed |
| EP-2651931-B1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2015-08-19 | — | — | EP | claimed |
| EP-2831064-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | claimed |
| EP-2651931-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2013-10-23 | — | — | EP | claimed |
| WO-2013144097-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | claimed |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-26 | — | — | US | claimed |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | claimed |
| WO-2012080476-A1 | FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | claimed |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| EP-3784664-B1 | 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4050005-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118286225-A | 2-Amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | 辉瑞公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024102952-A1 | SOS1 INHIBITORS | ACERAND THERAPEUTICS (USA) LIMITED (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| US-7157455-B2 | 4-Aminopyrimidine-5-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID J | 2006-10-12 | — | — | US | disclosed |
| EP-1628619-A2 | 4-AMINOPYRIMIDINE-5-ONE | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | BARTKOVITZ DAVID JOSEPH (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004069139-A2 | 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | AKR1C3 529/4885LMNA 869/4885ALDH1A1 1426/4885 |
| US-12378232-B2 | Cyclin dependent kinase inhibitors | CCNY, CCNI, CCNK | AKR1C3 2474/4885LMNA 1064/4885ALDH1A1 4211/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | AKR1C3 2033/4885LMNA 1854/4885ALDH1A1 3927/4885 |
| US-20040162303-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK6 | AKR1C3 2252/4885LMNA 3416/4885ALDH1A1 915/4885 |
| US-20060229330-A1 | 4-aminopyrimidine-5-one derivatives | CDK4, CDKL4, CDK2 | AKR1C3 3490/4885LMNA 3701/4885ALDH1A1 1191/4885 |
| US-20130252937-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS | GPR119, GPR55, GPR52 | AKR1C3 234/4885LMNA 4062/4885ALDH1A1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.